Autolus Therapeutics
AUTL
69 hedge funds and large institutions have $260M invested in Autolus Therapeutics in 2023 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 19 increasing their positions, 17 reducing their positions, and 8 closing their positions.
1,906% more call options, than puts
Call options by funds: $341K | Put options by funds: $17K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
63% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 8
33% more capital invested
Capital invested by funds: $195M → $260M (+$65.2M)
12% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 17
6% more funds holding
Funds holding: 65 → 69 (+4)
1.93% more ownership
Funds ownership: 61.28% → 63.21% (+1.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
+$21.9M |
| 2 |
TAM
TFG Asset Management
Grand Cayman,
Cayman Islands
|
+$4.75M |
| 3 |
AAA
Affinity Asset Advisors
New York
|
+$3.77M |
| 4 |
ECM
ExodusPoint Capital Management
New York
|
+$864K |
| 5 |
Two Sigma Investments
New York
|
+$511K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$8.11M |
| 2 |
AC
Armistice Capital
New York
|
-$5.71M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$3.27M |
| 4 |
JP Morgan Chase
New York
|
-$1.04M |
| 5 |
Millennium Management
New York
|
-$663K |
AUTL Hedge Fund Activity: Q2 2023 in Review
69 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Autolus Therapeutics (AUTL) for Q2 2023, worth a combined $260M — up 33% from $195M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new AUTL positions and 8 closed out — a net gain of 5 holders — while 19 added to existing stakes and 17 trimmed.
The largest buyer was Paradigm Biocapital Advisors, opening a new position worth an estimated $21.9M. The largest seller was Nantahala Capital Management, cutting an estimated $8.11M.
- 69 institutional investors held Autolus Therapeutics (AUTL) as of Q2 2023, up from 65 in Q1 2023.
- Funds reported $260M of Autolus Therapeutics stock for Q2 2023, up 33% quarter-over-quarter.
- 13 funds opened new Autolus Therapeutics positions in Q2 2023 and 8 closed out, a net change of +5 holders.
- The largest Autolus Therapeutics buyer in Q2 2023 was Paradigm Biocapital Advisors, an estimated $21.9M added.
- The largest Autolus Therapeutics seller in Q2 2023 was Nantahala Capital Management, an estimated $8.11M sold.
Based on aggregated 13F filings for Q2 2023.